Controlled Drugs and Substances Act

Legislative History and Framework

The Controlled Drugs and Substances Act received royal assent in 1996, marking a significant overhaul of Canada's drug control laws under the administration of Prime Minister Jean Chrétien. It was designed to repeal and replace the older Narcotic Control Act and relevant sections (Parts III and IV) of the Food and Drugs Act, creating a more modern and comprehensive statute. The Act establishes eight schedules (I through VIII) that list controlled substances, ranging from those deemed to have a high potential for abuse and no accepted medical use to those with lower risk profiles. It also creates two classes for precursor chemicals, which are substances used in the illicit manufacture of controlled drugs. A core feature of the CDSA is the authority it grants to the Governor in Council to amend the schedules by order, allowing the government to respond to emerging drug threats by adding or deleting substances as deemed necessary in the public interest. This framework enables Canada to meet its obligations under three United Nations drug control conventions: the Single Convention on Narcotic Drugs, the Convention on Psychotropic Substances, and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. The Act's structure intentionally separates the classification of substances from the regulations that authorize their legal use, a design that facilitated the major regulatory consolidation in 2026.

Key Schedules and Controlled Substances

The eight schedules of the CDSA categorize substances based on their perceived danger, therapeutic value, and international control status. Schedule I contains substances considered to have the most severe potential for harm and includes opioids like heroin, fentanyl, and oxycodone, stimulants like cocaine and methamphetamine, and other drugs like MDMA. Substances in Schedule I are subject to the most severe penalties for trafficking and production. Schedule II historically pertained to cannabis and its derivatives, but this schedule was effectively rendered obsolete by the coming into force of the Cannabis Act on October 17, 2018, which legalized and regulated cannabis separately. Schedules III and IV include substances with accepted medical uses but a potential for abuse, such as barbiturates, benzodiazepines like flunitrazepam, and anabolic steroids. Schedule V is specifically for substances temporarily controlled by ministerial order due to an immediate public health risk, such as the synthetic opioids spirochlorphine and spirobrorphine added in 2026. Schedules VI, VII, and VIII list various precursor chemicals used in drug production. The Act provides detailed chemical listings for each schedule, encompassing not only the named substances but also their salts, derivatives, isomers, and analogues to prevent circumvention through minor chemical modifications.

• Schedule I: Opium Poppy (Papaver somniferum), heroin (diacetylmorphine), fentanyl, carfentanil, cocaine, methamphetamine, MDMA (3,4-Methylenedioxyamphetamine), ketamine, GHB (4-hydroxybutanoic acid), MDPV (Methylenedioxypyrovalerone), tapentadol, and tramadol.
• Schedule III: Lysergic acid diethylamide (LSD), psilocybin, and mescaline.
• Schedule IV: Benzodiazepines including flunitrazepam, barbiturates, and anabolic steroids.
• Schedule V (Part 1): Temporarily controlled substances like spirochlorphine and spirobrorphine (added by ministerial order effective June 5, 2026).
• Precursors (Schedules V Part 2, VI, VII, VIII): Chemicals such as ephedrine, pseudoephedrine, and red phosphorus, with the 2026 Bill C-12 amendments enhancing control over Schedule V precursors.

Offences, Penalties and Historical Amendments

The CDSA creates a range of criminal offences related to controlled substances and precursors. Key offences include possession, trafficking (which includes selling, giving, transporting, or delivering), possession for the purpose of trafficking, importing and exporting, and production (cultivation or manufacture). Penalties vary significantly depending on the schedule of the substance, the type of offence, the quantity involved, and whether the offence involved aggravating factors such as violence, use of a weapon, or targeting young persons. For the most serious offences involving Schedule I and II substances, the Act originally allowed for life imprisonment. The Act has been amended several times to alter its penalty structure, most notably through bills that introduced mandatory minimum sentences. In November 2007, Justice Minister Rob Nicholson introduced Bill C-26 proposing mandatory minimum penalties for drug offences, which did not pass. A re-introduction as Bill C-15 passed the House of Commons in June 2009 but died when Parliament was prorogued in January 2010. The eventual passage of the Safe Streets and Communities Act, which received Royal Assent in March 2012, introduced mandatory minimum sentences of imprisonment for specific serious drug offences, particularly those involving trafficking or production of certain substances like cocaine, heroin, methamphetamine, and cannabis. These mandatory minimums apply to offences involving specific quantities and circumstances, such as trafficking near a school, but do not apply to the offence of simple possession. The Act also contains provisions for the forfeiture of offence-related property and the proceeds of crime. The Cannabis Act of 2018 created a separate legal regime for cannabis, removing simple possession and legal production from the scope of CDSA offences for that substance and making individuals with past cannabis possession records eligible for pardons from October 17, 2018.

Regulatory Framework and the 2026 Controlled Substances Regulations

Alongside its criminal provisions, the CDSA provides the authority for regulations that enable legitimate activities with controlled substances for medical, scientific, and industrial purposes. For decades, this was managed through multiple complex sets of regulations, including the Narcotic Control Regulations, the Benzodiazepines and Other Targeted Substances Regulations (BOTSR), and Parts G and J of the Food and Drug Regulations. A major modernization effort culminated in the creation of the new Controlled Substances Regulations (CSR), which were published in the Canada Gazette on December 17, 2025, and came into force on October 1, 2026. The CSR consolidates the previous multiple regulatory frameworks into a single, comprehensive set of rules, aiming to improve clarity, consistency and harmonization across all categories of controlled substances. This reform repeals the older regulations and integrates temporary authorities that had been granted under subsection 56(1) of the CDSA, such as certain prescription extensions and transfers by pharmacists, making them permanent features of the regulatory scene after the subsection 56(1) exemption expired on September 30, 2026. The CSR lists controlled substances in its Schedules 1 to 4, replacing the old schedule references, and establishes updated requirements for licensing, security, record-keeping, distribution, and disposal for healthcare practitioners, researchers, and licensed dealers. Health Canada's Controlled Substances Program conducted public consultations in 2024 before finalizing the regulations, and has provided guidance documents such as CS GD 022 for community pharmacy professionals.

• Pharmacy technicians and intern technicians are authorized to conduct specific activities with controlled substances under the regulations.
• Prior approval from Health Canada is no longer required for the destruction of controlled substances in many contexts.
• Pharmacies are no longer required to notify Health Canada when transferring controlled substance inventory after a permanent closure.
• Verbal prescriptions for controlled substances are accepted under the new framework.
• The authorities for persons in charge of a hospital to permit employees to handle controlled substances are clearly outlined.

Temporary Scheduling and the 2026 Bill C-12 Amendments

To address the rapid emergence of novel psychoactive substances, the CDSA includes an accelerated temporary scheduling mechanism under subsection 60.1(1). This provision allows the Minister of Health to temporarily add a substance to Schedule V of the Act by ministerial order if the Minister has reasonable grounds to believe it poses a significant risk to public health or safety. Once added, all activities such as import, export, possession for the purpose of exportation, production, and trafficking are prohibited unless authorized by Health Canada. This process was used in 2026 to add the synthetic opioids spirobrorphine and spirochlorphine to Schedule V. The ministerial order (SOR/2026-71) cited evidence that spirochlorphine has been detected in the Canadian and international illegal drug markets, intercepted at the border, and contributed to fatal and non-fatal overdoses, while spirobrorphine is chemically related and had been detected internationally. The order came into force on June 5, 2026. The CDSA was amended by Bill C-12, the Strengthening Canada's Immigration System and Borders Act, which received Royal Assent on March 26, 2026. Part 2 of this bill amended the temporary scheduling pathway to explicitly allow the Minister of Health to regulate chemicals listed in Schedule V as precursors, enhancing the government's ability to control substances used in the illicit manufacture of drugs like fentanyl. These tools are critical for an agile response to the evolving illegal drug supply, and under the new CSR, temporarily scheduled controlled substances are listed in Part 3 of Schedule 4 to the CSR, requiring a controlled substance licence or other authorization from Health Canada for any permitted activity.

Impact on Healthcare Practice and Provincial Interaction

The CDSA and its regulations have a direct impact on the daily practice of healthcare professionals in Canada, particularly pharmacists, physicians, and nurses. The framework governs how controlled substances are prescribed, dispensed, stored, recorded, and destroyed. The 2026 introduction of the Controlled Substances Regulations brought significant changes to pharmacy operations. It permanently authorized activities that were previously temporary under the subsection 56(1) exemption, such as pharmacists extending (renewing) and transferring prescriptions for controlled substances under specific conditions. However, professional practice remains subject to provincial legislation and bylaws, which can impose stricter limits than the federal rules. For example, while the federal CSR may allow certain therapeutic substitutions, provincial scopes of practice in Ontario and British Columbia explicitly prohibit this for controlled substances because it is not included in their provincial legislation. Pharmacists must follow both federal quantity limits for prescription extensions and more restrictive provincial limits on renewal quantities. Provincially, pharmacists in Ontario can renew a controlled substance for a quantity that does not exceed the lesser of a 30-day supply or the original prescribed amount. Federally, the CSR allows an extension if the quantity does not exceed a days' supply that would last more than two years after the prescription was first received. This dual layer of regulation means healthcare providers must be aware of the specific rules in their province, which are often more limiting. The changes also affect hospital settings, where persons in charge can permit employees, including pharmacy professionals, to conduct activities with controlled substances as outlined in the CSR. Health Canada has conducted information sessions focused on the implications for community pharmacies, acknowledging that hospital and specialized settings would be addressed separately.

Interaction with Other Legislation and International Context

The CDSA does not operate in isolation but interacts with several other key pieces of Canadian and international legislation. Its most notable interaction is with the Cannabis Act, which came into effect on October 17, 2018. The Cannabis Act created a separate legal framework for the production, distribution, sale, and possession of cannabis, effectively removing it from the ambit of the CDSA for legal activities. This change also made individuals with past criminal records solely for cannabis possession eligible for pardons from that date. The CDSA also works in conjunction with the Customs Act and the Criminal Code for enforcement at borders and for investigating related crimes such as conspiracy or organized crime offences linked to drug trafficking. The Food and Drugs Act continues to regulate the safety, efficacy, and quality of all drugs, including controlled substances that have approved therapeutic uses. The recent regulatory consolidation under the Controlled Substances Regulations simplifies this interaction by merging the controlled substance aspects of the Food and Drug Regulations into the new single framework, reducing regulatory overlap for stakeholders. The CDSA is Canada's implementing legislation for the Single Convention on Narcotic Drugs, the Convention on Psychotropic Substances, and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.

Enforcement and Compliance Structures

Enforcement of the Controlled Drugs and Substances Act involves multiple federal agencies, primarily Health Canada's Compliance and Enforcement Program, the Royal Canadian Mounted Police (RCMP), the Canada Border Services Agency (CBSA), and provincial and municipal police forces. Health Canada is responsible for administering the regulatory framework, issuing licences and permits for legitimate activities, and conducting inspections of licensed dealers, pharmacies, hospitals, and researchers to ensure compliance with security, record-keeping, and reporting requirements. The RCMP and CBSA focus on intercepting illicit drugs and precursors at the border and investigating domestic trafficking and production networks. The CDSA provides inspectors with powers to enter premises, examine records, and seize substances found in contravention of the Act or its regulations. For substances temporarily added to Schedule V, the CBSA and RCMP are empowered to detain and seize shipments immediately upon the order coming into force. The 2026 amendments via Bill C-12 are part of a broader government effort to strengthen border security against illegal drugs. Compliance for healthcare professionals is supported by guidance documents from Health Canada and provincial regulatory colleges, which outline standards for activities like prescription adaptation, inventory management, and accepting verbal orders. The consolidation of regulations in 2026 is intended to reduce complexity and improve compliance by having a single set of rules for all controlled substances, replacing the previous patchwork of the Narcotic Control Regulations, Benzodiazepine and Other Targeted Substances Regulations, and Parts G and J of the Food and Drug Regulations.

Questions about Controlled Drugs and Substances Act

What is the Controlled Drugs and Substances Act?

The Controlled Drugs and Substances Act is Canada's main federal law that controls drugs and chemicals that can be used to make drugs. It was passed in 1996 and sets up rules about which substances are illegal, what the penalties are for breaking those rules, and how some drugs can be used legally by doctors and scientists. The law has eight schedules that list different drugs based on how dangerous they are, and it is the law Canada uses to follow international drug treaties including the Single Convention on Narcotic Drugs. The Act was amended in 2026 by Bill C-12 to strengthen controls on precursor chemicals.

What changed with the new Controlled Substances Regulations in 2026?

On October 1, 2026, the new Controlled Substances Regulations came into effect, replacing the Narcotic Control Regulations, the Benzodiazepines and Other Targeted Substances Regulations, and Parts G and J of the Food and Drug Regulations. This creates one single framework for all federal rules on controlled substances. The regulations make permanent the temporary rules that let pharmacists extend and transfer prescriptions, which had been in place under a subsection 56(1) exemption. They also remove the requirement for pharmacy closure inventory transfers to be reported to Health Canada and eliminate the need for prior approval for destroying controlled substances in many cases. The regulations also authorize pharmacy technicians to handle controlled substances.

What are the penalties for breaking the CDSA?

Penalties under the CDSA depend on the drug and the crime. For serious crimes like trafficking or producing drugs listed in Schedule I, such as fentanyl or cocaine, penalties can include life imprisonment. The law also has mandatory minimum sentences for certain serious offences involving specific drugs and quantities, established by the Safe Streets and Communities Act of 2012. For simple possession of a Schedule I, II, or III substance, the maximum penalty if tried as an indictable offence is 3 years, 2 years, or 1 year imprisonment respectively. Simple possession of a Schedule IV substance for personal use is not an offence. The law also allows for fines and the forfeiture of property or money earned from drug crimes.

How does the CDSA handle new synthetic drugs?

The CDSA has a special tool to quickly ban new synthetic drugs under subsection 60.1(1). The Minister of Health can temporarily add a substance to Schedule V of the Act by ministerial order if there are reasonable grounds to believe it poses a significant risk to public health or safety. This was done in 2026 for synthetic opioids called spirochlorphine and spirobrorphine, with the order taking effect on June 5, 2026. Once added, it becomes illegal to import, make, or sell these substances without permission from Health Canada. Bill C-12, passed in March 2026, expanded this power to better control precursor chemicals listed in Schedule V.

Can pharmacists refill prescriptions for controlled drugs?

Yes, but with specific rules that involve both federal and provincial limits. Under the Controlled Substances Regulations that started in October 2026, pharmacists can extend (renew) a prescription for a controlled substance. Federally, the extension cannot be for a quantity that would last more than two years after the prescription was first received. However, provincial laws often have stricter rules. For example, Ontario limits a renewal to the lesser of a 30-day supply or the original prescribed amount. Pharmacists must apply the stricter of the two limits, and therapeutic substitution of one controlled substance for another remains prohibited in provinces like Ontario and British Columbia.

How does the Cannabis Act relate to the CDSA?

The Cannabis Act, which started on October 17, 2018, created a completely separate system for legal cannabis. It took cannabis out of the CDSA for legal activities, meaning growing, selling, and possessing cannabis within legal limits is no longer a crime under the CDSA. The Cannabis Act also allowed people with old criminal records only for cannabis possession to apply for a pardon starting from that date. The CDSA still controls all other illegal drugs, and its Schedule II, which once listed cannabis, is now effectively obsolete for enforcement purposes related to simple possession or legal production. Schedules VII and VIII of the CDSA, which set possession limits for cannabis, were also repealed by the Cannabis Act.

Sources and further reading

• Controlled Drugs and Substances Act (Wikipedia)
• Health Canada's Controlled Substances Regulations take ... (abpharmacy.ca)
• Controlled Substances Regulations (ocpinfo.com)
• New Controlled Substances Regulations in Effect October ... (bcpharmacists.org)
• SOR/2026-71 (gazette.gc.ca)

Checked by the Nosy Mag desk. Last updated 2026-10-22.